Principal Financial Group
BDTX icon

Principal Financial Group’s Black Diamond Therapeutics BDTX Stock Holding History

Principal Financial Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,414
Closed -$238K – 2481
2020
Q4 		$238K Buy
+7,414
New +$244K ﹤0.01% 2279

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Principal Financial Group's BDTX Position: Q1 2021 in Review

Principal Financial Group sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 7,414 shares — an estimated $238K sold.

Principal Financial Group first reported a position in BDTX in Q4 2020 and held it in 1 quarter. The position peaked at $238K in Q4 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

  • Principal Financial Group reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Principal Financial Group sold 7,414 Black Diamond Therapeutics shares in Q1 2021, an estimated $238K.
  • Principal Financial Group first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 1 quarter.
  • Principal Financial Group's Black Diamond Therapeutics position peaked at $238K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on Principal Financial Group's 13F filing for Q1 2021, filed 10 May 2021.